Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taliglucerase alfa - Pfizer/Protalix Biotherapeutics

Drug Profile

Taliglucerase alfa - Pfizer/Protalix Biotherapeutics

Alternative Names: Alfataliglicerase; BioManguinhos alfataliglicerase; Elelyso; Glucocerebrosidase; Oral GCD; prGCD; PRX-112; Uplyso

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protalix Biotherapeutics
  • Developer Pfizer; Protalix BioTherapeutics
  • Class Glucosidases; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gaucher's disease

Most Recent Events

  • 27 Feb 2023 Launched for Gaucher's disease in Russia (IV)
  • 05 Oct 2022 Launched for Gaucher's disease (In children, In adults) in Canada (IV)
  • 01 Dec 2018 Efficacy and adverse events data from an expanded access trial in Gaucher Disease presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top